• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Australia·Healthcare·EPN.AX
Share

Epsilon Healthcare Limited Stocks

A$ 0.02Last Updated 22.10.2026

Issuer Rating

2/7
Performance

Modest

Risk

High

Recommendation

Sell

Market Cap

A$ 6.22M

A$ 0.02
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Very low or no dividends

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Epsilon Healthcare Limited operates as an Australian-based healthcare and pharmaceutical firm, with significant operations also extending into Canada. Established in 2016 and headquartered in Sydney, the company specializes in several areas: manufacturing and distributing a range of hydroponic supplies, including equipment, materials, and vital nutrients; developing and providing medicinal cannabis products; and offering comprehensive, ready-to-implement solutions for cannabis cultivation. The company officially rebranded from THC Global Group Limited to Epsilon Healthcare Limited in February 2021.

Company Valuation

Fairly valued
4/7

From both historical and forecast perspectives, the stock is fairly priced compared to similar stocks. In particular, the stock is overpriced on P/E, trading at neutral l

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

22.10.2026 22:26

Apple shares have become a "safe haven" amid concerns over AI spending. Should you buy them?

22.10.2026 21:37

Alibaba's stock has fallen the most in two months. What's weighing on it?

22.10.2026 20:57

Revolut has received its first credit rating. S&P anticipates the fintech company's entry into the bond market

22.10.2026 20:15

Meta's stock is heading for its worst day since July. Its credit risk has peaked due to AI spending

22.10.2026 19:34

A merger between Tesla and SpaceX could net Musk more than $110 billion. What are the risks for shareholders?

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026